AR033973A1 - Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprende - Google Patents
Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprendeInfo
- Publication number
- AR033973A1 AR033973A1 ARP010101264A ARP010101264A AR033973A1 AR 033973 A1 AR033973 A1 AR 033973A1 AR P010101264 A ARP010101264 A AR P010101264A AR P010101264 A ARP010101264 A AR P010101264A AR 033973 A1 AR033973 A1 AR 033973A1
- Authority
- AR
- Argentina
- Prior art keywords
- cabergoline
- form vii
- treatment
- vii
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se divulgan una Forma VII cristalina de cabergolina, una composición farmacéutica que la contiene y un proceso para su preparación. El proceso puede comprender un procedimiento de mezcla que utiliza la forma I o mezcla de las formas I y VII de cabergolina, en un solvente, a una temperatura superior a 30°C. La cabergolina es un derivado de la ergolina que interactúa con receptores de la dopamina D2 y está dotada de diferentes actividades farmacéuticas útiles. La misma se utiliza en el tratamiento de la hiperprolactinemia, desórdenes del sistema nervioso central (SNC) y otras enfermedades relacionadas. La Forma VII de cabergolina exhibe un efecto inhibidor significativo con respecto a la prolactina. La cabergolina también es activa, sola o en combinación, en el tratamiento de enfermedades obstructivas reversibles de los conductos respiratorios, para controlar la presión intraocular y para el tratamiento de glaucomas. También se emplea en el ámbito veterinario, como agente de antiprolactina y para reducir drásticamente la proliferación de animales vertebrados. La Forma VII resulta particularmente útil en el tratamiento de la enfermedad de Parkinson (EP), Síndrome de Piernas Inquietas (SPI), tratamiento de enfermedades como Parálisis Supranuclear Progresiva (PSP) y atrofia Multisistémica (AMS).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007309.8A GB0007309D0 (en) | 2000-03-24 | 2000-03-24 | Crystalline form V|| of cabergoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033973A1 true AR033973A1 (es) | 2004-01-21 |
Family
ID=9888434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101264A AR033973A1 (es) | 2000-03-24 | 2001-03-19 | Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprende |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6680327B2 (es) |
| EP (1) | EP1265894A1 (es) |
| JP (1) | JP2003528873A (es) |
| AR (1) | AR033973A1 (es) |
| AU (1) | AU780744B2 (es) |
| CA (1) | CA2403557A1 (es) |
| GB (1) | GB0007309D0 (es) |
| MY (1) | MY125975A (es) |
| NZ (1) | NZ521317A (es) |
| PE (1) | PE20011076A1 (es) |
| WO (1) | WO2001072746A1 (es) |
| ZA (1) | ZA200207296B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
| GB0007308D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Process for preparing crystalline form | of cabergoline |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| IL163520A0 (en) * | 2002-03-15 | 2005-12-18 | Pharmacia Italia Spa | Process for preparing crystalline form i of cabergoline |
| IL155545A (en) * | 2003-04-21 | 2009-12-24 | Finetech Pharmaceutical Ltd | Solvate form of cabergoline |
| EP1620101A4 (en) | 2003-05-08 | 2008-07-09 | Ivax Pharmaceuticals Sro | POLYMORPHS OF CABERGOLIN |
| GB0409785D0 (en) * | 2004-04-30 | 2004-06-09 | Resolution Chemicals Ltd | Preparation of cabergoline |
| US7339060B2 (en) | 2005-03-23 | 2008-03-04 | Resolution Chemicals, Ltd. | Preparation of cabergoline |
| GB0505965D0 (en) | 2005-03-23 | 2005-04-27 | Resolution Chemicals Ltd | Preparation of cabergoline |
| EP1925616A1 (en) * | 2006-10-26 | 2008-05-28 | LEK Pharmaceuticals D.D. | Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline |
| EP1953157A1 (en) | 2007-01-31 | 2008-08-06 | LEK Pharmaceuticals D.D. | New crystal form of cabergoline |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| GB2103603B (en) * | 1981-08-11 | 1985-04-11 | Erba Farmitalia | Ergoline derivatives |
| SK13312000A3 (sk) * | 1998-03-27 | 2001-05-10 | Pharmacia And Upjohn Company | Použitie kabergolínu pri liečbe syndrómu nepokojných nôh |
| PL344574A1 (en) * | 1998-05-15 | 2001-11-05 | Upjohn Co | Cabergoline and pramipexole: new uses and combinations |
| GB0007307D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form || of cabergoline |
-
2000
- 2000-03-24 GB GBGB0007309.8A patent/GB0007309D0/en not_active Ceased
-
2001
- 2001-02-12 PE PE2001000149A patent/PE20011076A1/es not_active Application Discontinuation
- 2001-03-15 WO PCT/EP2001/002969 patent/WO2001072746A1/en not_active Application Discontinuation
- 2001-03-15 NZ NZ521317A patent/NZ521317A/en unknown
- 2001-03-15 EP EP01925471A patent/EP1265894A1/en not_active Ceased
- 2001-03-15 US US10/221,165 patent/US6680327B2/en not_active Expired - Fee Related
- 2001-03-15 CA CA002403557A patent/CA2403557A1/en not_active Abandoned
- 2001-03-15 JP JP2001570656A patent/JP2003528873A/ja not_active Withdrawn
- 2001-03-15 AU AU52211/01A patent/AU780744B2/en not_active Ceased
- 2001-03-19 AR ARP010101264A patent/AR033973A1/es unknown
- 2001-03-22 MY MYPI20011365A patent/MY125975A/en unknown
-
2002
- 2002-09-11 ZA ZA200207296A patent/ZA200207296B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6680327B2 (en) | 2004-01-20 |
| AU780744B2 (en) | 2005-04-14 |
| JP2003528873A (ja) | 2003-09-30 |
| ZA200207296B (en) | 2003-09-11 |
| GB0007309D0 (en) | 2000-05-17 |
| EP1265894A1 (en) | 2002-12-18 |
| CA2403557A1 (en) | 2001-10-04 |
| MY125975A (en) | 2006-09-29 |
| WO2001072746A1 (en) | 2001-10-04 |
| AU5221101A (en) | 2001-10-08 |
| NZ521317A (en) | 2004-06-25 |
| US20030144516A1 (en) | 2003-07-31 |
| PE20011076A1 (es) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033973A1 (es) | Forma vii cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, un proceso para producir dicha forma vii, y una composicion farmaceutica que la comprende | |
| BR0112756A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| IL156261A0 (en) | Pyrroloquinoline and pyridoquinoline derivatives and pharmaceutical compositions containing the same | |
| BRPI0512418A (pt) | derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, compostos, antagonista para receptores de crf, uso de um derivado de pirrolpirimidina ou pirrolpiridina substituìdo com um grupo amino cìclico, de um sal do mesmo e de seu hidrato farmaceuticamente aceitáveis | |
| BRPI0416752A (pt) | composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| BR0315234A (pt) | Derivados de indol como agonistas beta-2 | |
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| AR027548A1 (es) | Derivados de amino pirazol utiles para el tratamiento de la obesidad y otros desordenes | |
| BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
| AR031248A1 (es) | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| WO2007134107A3 (en) | Cold menthol receptor-1 antagonists | |
| PE20020911A1 (es) | Derivados de indol como agonistas de 5ht2 | |
| IS7891A (is) | Skiptitengd þrísýklísk gamma-karbólín sem serótónín viðtaka gerandefni og mótverkunarefni | |
| GT200100147A (es) | Derivados de imidazol | |
| UA84192C2 (en) | Hydroisoindoline tachykinin receptor antagonists | |
| CL2003002050A1 (es) | Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central. | |
| BRPI0814382A2 (pt) | Composto, uso do composto, e, composição farmacêutica | |
| CR10387A (es) | Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor | |
| AR036208A1 (es) | Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
| AR032449A1 (es) | Un procedimiento para producir la forma i cristalina de cabergolina, es decir, 1((6-alilergolin-8beta-il)-carbonil)-1-(3-dimetilaminopropil)-3-etilurea, forma v de solvato de cabergolina, y un procedimiento para producir la forma v de solvato de cabergolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |